Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Pain. 2018 Dec;159(12):2620–2629. doi: 10.1097/j.pain.0000000000001373

Figure 1. Intrathecal delivery of KLA induces tactile allodynia that is unresponsive to NSAIDs.

Figure 1.

(A). Time course and (B) percent hyperalgesic index or AUC values reveal that spinal pretreatment with the COX-1/2 inhibitor ketorolac (50 μg IT) has no significant effect on IT KLA-induced pain hypersensitivity. **P<0.01 v. VEH; n.s., not significantly different from VEH. VEH, vehicle; KETO, ketorolac; KLA, KDO2-Lipid A.